B001-C
/ Shanghai Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
July 17, 2024
A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD)
(clinicaltrials.gov)
- P2/3 | N=132 | Not yet recruiting | Sponsor: Shanghai Jiaolian Drug Research and Development Co., Ltd | Initiation date: Jun 2024 ➔ Sep 2024
Trial initiation date • CNS Disorders • Neuromyelitis Optica Spectrum Disorder • Rare Diseases
July 24, 2024
A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD)
(clinicaltrials.gov)
- P2/3 | N=132 | Recruiting | Sponsor: Shanghai Jiaolian Drug Research and Development Co., Ltd | Not yet recruiting ➔ Recruiting
Enrollment open • CNS Disorders • Neuromyelitis Optica Spectrum Disorder • Rare Diseases
1 to 2
Of
2
Go to page
1